Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 384, Issue 1, 2011, Pages 39-45

  Rung, Johan P ^a,b   Rung, Emilia ^b   Johansson, Anette M ^c   Svensson, Kjell ^c   Carlsson, Arvid ^a,b   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b A Carlsson Research AB   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

(S) ( ) OSU6162; ACR16; Dopaminergic stabilizers; Prolactin secretion; Rat

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; ARIPIPRAZOLE; DOPAMINE; HALOPERIDOL; METIROSINE; PRECLAMOL; PRIDOPIDINE; PROLACTIN; RESERPINE;

ANIMAL EXPERIMENT; ARTICLE; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; HORMONE RELEASE; IN VIVO STUDY; MALE; NONHUMAN; PROLACTIN BLOOD LEVEL; RAT;

ANIMALS; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; HYPERPROLACTINEMIA; LACTOTROPHS; MALE; METHYLTYROSINES; PIPERAZINES; PIPERIDINES; PROLACTIN; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RESERPINE;

EID: 79959379818     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0641-y     Document Type: Article

References (21)

1. M Carlsson A Carlsson E Eriksson 1987 The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats Eur J Pharmacol 142 1 39 43 3691635 10.1016/0014-2999(87)90651-0 1:CAS:528:DyaL2sXmt12rt70%3D (Pubitemid 17159905)
2. T Dyhring EO Nielsen C Sonesson F Pettersson J Karlsson P Svensson P Christophersen N Waters 2010 The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties Eur J Pharmacol 628 1-3 19 26 10.1016/j.ejphar.2009.11. 025 19919834 10.1016/j.ejphar.2009.11.025 1:CAS:528:DC%2BC3cXnvFOksQ%3D%3D
3. A Ekesbo R Torstenson P Hartvig A Carlsson C Sonesson N Waters J Tedroff B Långstrom 1999 Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains Neuropharmacology 38 3 331 338 10219971 10.1016/S0028-3908(98) 00200-7 1:CAS:528:DyaK1MXit1ersbk%3D (Pubitemid 29097716)
4. E Eriksson K Modigh A Carlsson H Wikstrom 1983 Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers Eur J Pharmacol 96 1-2 29 36 6662196 10.1016/0014-2999(83) 90525-3 1:CAS:528:DyaL2cXpslWqtQ%3D%3D (Pubitemid 14222406)
5. Gefvert O, Lindström LH, Dahlbäck O, Sonesson C, Waters N, Carlsson A, Tedroff J (2000) (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled pilot study. In: von Knorring L (ed) 41st annual meeting, Scandinavian Society for Psychopharmacology, Copenhagen, Denmark, April 2000. Nord J Psychiat 54(2):93-94
6. T Inoue M Domae K Yamada T Furukawa 1996 Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland J Pharmacol Exp Ther 277 1 137 143 8613910 1:CAS:528:DyaK28XitlCmtr0%3D
7. E Kara H Lin K Svensson AM Johansson PG Strange 2010 Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor British journal of pharmacology 161 6 1343 1350 10.1111/j.1476-5381.2010.01010.x 20804495 10.1111/j.1476-5381.2010.01010.x 1:CAS:528:DC%2BC3cXhsFWhsrrP
8. DL Kelly RR Conley 2004 Sexuality and schizophrenia: a review Schizophr Bull 30 4 767 779 15954189 (Pubitemid 40469514)
9. AC Lahti MA Weiler PK Corey RA Lahti A Carlsson CA Tamminga 1998 Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine(preclamol) in schizophrenia Biol Psychiatry 43 1 2 11 9442338 10.1016/S0006-3223(97)00030-9 1:CAS:528:DyaK1cXjslCkuw%3D%3D (Pubitemid 28059067)
10. RA Lahti CA Tamminga A Carlsson 2007 Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D(2) receptor function in vitro J Neural Transm 114 9 1143 1146 10.1007/s00702-007-0784-7 17612788 10.1007/s00702-007-0784-7 1:CAS:528:DC%2BD2sXpsFWqu7c%3D (Pubitemid 47313178)
11. Lundberg T, Tedroff J, Waters N, Sonesson C, Carlsson A, Hagström P, Lindström LH, Gefvert O (2002) Safety of early clinical experience with (-)-OSU6162, a dopaminergic stabilizer with antipsychotic properties. In: 43rd Annual and 2nd Mediterranean Meeting, Scandinavian College of Neuro-Psychopharmacology, Juan-les-Pins, France, April 2002. Nord J Psychiat 56(2):111
12. A Lundin E Dietrichs S Haghighi ML Goller A Heiberg G Loutfi H Widner K Wiktorin L Wiklund A Svenningsson C Sonesson N Waters S Waters J Tedroff 2010 Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease Clinical neuropharmacology 33 5 260 264 10.1097/WNF.0b013e3181ebb285 20616707 10.1097/WNF.0b013e3181ebb285 1:CAS:528:DC%2BC3cXht1WisrbF
13. S Natesan KA Svensson GE Reckless JN Nobrega KB Barlow AM Johansson S Kapur 2006 The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl- piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat J Pharmacol Exp Ther 318 2 810 818 16648369 10.1124/jpet.106.102905 1:CAS:528:DC%2BD28XnslOltrY%3D (Pubitemid 44061255)
14. NF Nichols MG Cimini JV Haas BA Staton J Tedroff KA Svensson 2002 PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease Neuropharmacology 43 5 817 824 12384167 10.1016/S0028-3908(02)00144-2 1:CAS:528:DC%2BD38XnvVGqsL0%3D (Pubitemid 35217722)
15. JP Rung A Carlsson K Rydén Markinhuhta ML Carlsson 2005 The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats Prog Neuropsychopharmacol Biol Psychiatry 29 5 833 839 15913873 10.1016/j.pnpbp.2005.03.003 1:CAS:528:DC%2BD2MXlslymur0%3D (Pubitemid 40897801)
16. JP Rung E Rung L Helgeson AM Johansson K Svensson A Carlsson ML Carlsson 2008 Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization J Neural Transm 115 6 899 908 10.1007/s00702-008-0038-3 18351286 10.1007/s00702-008-0038-3 1:CAS:528:DC%2BD1cXmslWku7Y%3D
17. P Seeman HC Guan 2007 Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis Eur J Pharmacol 557 2-3 151 153 10.1016/j.ejphar.2006.11.016 17157291 10.1016/j.ejphar.2006.11.016 1:CAS:528:DC%2BD2sXhtlWiu7s%3D (Pubitemid 46188631)
18. C Sonesson CH Lin L Hansson N Waters K Svensson A Carlsson MW Smith H Wikström 1994 Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships J Med Chem 37 17 2735 2753 8064801 10.1021/jm00043a013 1:CAS:528:DyaK2cXlt1Cmu7Y%3D (Pubitemid 24273465)
19. Svensson KA, Falcone JF, Johansson AM, Perry KW, Fell MJ (2009) The actions of the dopamine stabilizer ACR16, but not (-)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional dopamine D2 receptors. In: 39th Annual Meeting, Society for Neuroscience, Chicago, October 2009
20. J Tedroff A Ekesbo C Sonesson N Waters A Carlsson 1999 Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease Neurology 53 7 1605 1606 10534281 1:STN:280:DC%2BD3c%2FgtFynug%3D%3D (Pubitemid 29491967)
21. MD Wood C Scott K Clarke J Westaway CH Davies C Reavill M Hill C Rourke M Newson DN Jones IT Forbes A Gribble 2006 Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties Eur J Pharmacol 546 1-3 88 94 16925992 10.1016/j.ejphar.2006.07.008 1:CAS:528:DC%2BD28XpsVWqu7g%3D (Pubitemid 44339632)